CHP2 (M136) polyclonal Antibody | BS3273

CHP2 (M136) polyclonal Antibody | BS3273 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: WB

Application Range: WB: 1:500~1:1000

Background: Calcineurin B homologous protein 2, functions as an integral cofactor in cell pH regulation by controlling plasma membrane-type Na+/H+ exchange activity. Binds to and activates SLC9A1/NHE1 in a serum-independent manner, thus increasing pH and protecting cells from serum deprivation-induced death. Also plays a role in the regulation of cell proliferation and tumor growth by increasing the phosphatase activity of PPP3CA in a calcium-dependent manner. Activator of the calcineurin/NFAT signaling pathway. Involved in the cytoplasmic translocation of the transcription factor NFATC3 to the nucleus.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: CHP2 pAb detects endogenous levels of CHP2 protein.

Molecular Weight: ~ 23 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: Serine/threonine-protein kinase MARK1; MAP/microtubule affinity-regulating kinase 1; PAR1 homolog c; Par-1c; Par1c; MARK1; KIAA1477; MARK; Serine/threonine-protein kinase MARK2 ; ELKL motif kinase 1; EMK-1; MAP/microtubule affinity-regulating kinase 2; PAR1 homolog; PAR1 homolog b; Par-1b; Par1b; MARK2; EMK1; MAP/microtubule affinity-regulating kinase 3; C-TAK1; cTAK1; Cdc25C-associated protein kinase 1; ELKL motif kinase 2; EMK-2; Protein kinase STK10; Ser/Thr protein kinase PAR-1; Par-1a; Serine/threonine-protein kinase p78; MARK3; CTAK1; EMK2; MAP/microtubule affinity-regulating kinase 4; MAP/microtubule affinity-regulating kinase-like 1; MARK4; KIAA1860; MARKL1

Immunogen: Synthetic peptide, corresponding to amino acids 122-182 of Human MARK1/2/3/4.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: